Bemarituzumab
- Generic Name
- Bemarituzumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1952272-74-0
- Unique Ingredient Identifier
- RJW23BQ0KW
- Background
Bemarituzumab is under investigation in clinical trial NCT03694522 (A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (Mfolfox6) in Gastric/gastroesophageal Junction Cancer (FIGHT)).
- Associated Conditions
- -
- Associated Therapies
- -
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Amgen
- Target Recruit Count
- 303
- Registration Number
- NCT05325866
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸University of California Irvine, Orange, California, United States
🇺🇸Rocky Mountain Cancer Centers, Aurora, Colorado, United States
A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.
Phase 1
Recruiting
- Conditions
- Gastroesophageal Junction CancerGastric Cancer
- Interventions
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Amgen
- Target Recruit Count
- 80
- Registration Number
- NCT05322577
- Locations
- 🇯🇵
Gifu University Hospital, Gifu-shi, Gifu, Japan
🇺🇸Northport Veterans Affairs Medical Center, Northport, New York, United States
🇯🇵Fujita Health University Hospital, Toyoake-shi, Aichi, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath